Meet the Team

---

Michael Howell, PhD is an immunologist with more than 25 years of experience in the government, academia, and the biopharma/biotech sectors.  Dr. Howell was a faculty member at National Jewish Health, and held roles of increasing responsibility at Boehringer Ingelheim, Immune Tolerance Network, MedImmune/AstraZeneca, and the Incyte Corporation.  Dr. Howell has previously led research and development teams dedicated to the discovery of novel therapies and the integration of novel biomarker approaches into clinical development.  His efforts have led to the approval of multiple therapies including Opzelura (ruxolitinib), Jakafi (ruxolitinib), Adbry/Adtralza (tralokinumab), Tezpire (tezepelumab), Skyrizi (rizankizumab), and others; novel diagnostic approaches to patient treatment, and have been highlighted in more than 60 publications and numerous patents.  Dr. Howell received his PhD in Immunology from West Virginia University School of Medicine and completed his post-doctoral training at National Jewish Health.